Medical Dialogues
  • Dermatology
Sign in Signup
This site is intended for healthcare professionals only
Sign in Signup
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
Medical Dialogues
  • Medical News
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Medical Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
  • MDTV
      • Anesthesia
      • CTVS
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • Diet and nutrition
      • ENT
      • Gastroenterology
      • Health Dialogues
      • Health News today
      • Health Shorts
      • Health Updates
      • Health video of the day
      • Laboratory Medicine
      • Latest Videos
      • Latest Webinars
      • MD shorts
      • Medical News Today
      • Medical Updates
      • Medical Video of the day
      • Medicine
      • Medico Legal Update
      • Nephrology
      • Neurology and Neurosurgery
      • Obstetrics and Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics & Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Top Videos
      • Urology
This site is intended for healthcare professionals only
Sign InRegister
Medical Dialogues
Sign inRegister
  • Home
  • Medical news
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Medical Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
  • Case of the Day
  • Editorial
  • Home
  • News
  • Industry
  • Pharma News
  • Torrent Pharma...

Torrent Pharma Tapentadol Nasal Spray gets CDSCO panel go ahead for phase 3 trial

Medical Dialogues TeamBy Medical Dialogues TeamPublished On 2021-08-17T15:40:09+05:30  |  Updated On 17 Aug 2021 10:10 AM GMT
Torrent Pharma Tapentadol Nasal Spray gets CDSCO panel go ahead for phase 3 trial

New Delhi: The Ahmedabad-based pharmaceutical major, Torrent Pharma, has received permission from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase III Clinical Trial of Tapentadol Nasal Spray 225mg/ml, which is used to relieve moderate to severe short-term pain.However, the SEC approval came with conditions, wherein the expert...

New Delhi: The Ahmedabad-based pharmaceutical major, Torrent Pharma, has received permission from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase III Clinical Trial of Tapentadol Nasal Spray 225mg/ml, which is used to relieve moderate to severe short-term pain.

However, the SEC approval came with conditions, wherein the expert panel directed the firm that a waiting period of 60 minutes for administering the rescue medication is not acceptable and it should be reduced to 30 minutes. In addition, the committee also instructed the firm to include the standard of care in an amended version of the protocol that would be delivered to all patients in three sub-groups.

This recommendation came after the drug-maker presented the revised Phase III clinical trial (CT) protocol for Tapentadol Nasal Spray 225mg/ml before the Committee at a recent SEC meeting for analgesics and rheumatology.

Also Read:Revise phase 3 clinical trial protocol for Tapentadol Nasal Spray: CDSCO panel tells Torrent Pharma

Tapentadol is a centrally acting analgesic having both m-opioid receptor agonist and noradrenalin (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. This dual mode of action makes tapentadol particularly useful in the treatment of both nociceptive pain and neuropathic pain.

Tapentadol is available commercially under the brand name NUCYNTA as 50mg, 75mg, and 100 mg oral tablets, indicated for the relief of moderate to severe acute pain.

The Medical Dialogues Team had reported earlier that following the Torrent Pharma's proposal for manufacturing and marketing of Tapentadol Nasal Spray 225mg/ml, the CDSCO Committee, at its 72nd SEC meeting for Analgesics & Rheumatology held on 24.06.2021 & 25.06.2021, had recommended the firm to revise the Phase III CT protocol according to the following conditions:

1. The subject population included patients from 3 different clinical indications. All these sub-group patients should be clearly defined in terms of clinical presentation/pain scores.

2. Sample size should be recalculated based on statistical calculation & justifiable in these 3 sub-groups.

3. Study design should be modified & it should preferably be blinded.

4. The rescue medications should be changed as the test products are opioids (Tapentadol & Tramadol).

Accordingly, at the 74th SEC meeting for Analgesics & Rheumatology, in light of earlier SEC recommendations dated 24.06.2021 & 25.06.2021, the firm presented the revised Phase III CT protocol for Tapentadol Nasal Spray 225mg/ml before the Committee.

After detailed deliberation, the committee recommended the grant of permission to conduct the Phase III Clinical Trial as per protocol presented subject to the following conditions.

1. The waiting period of 60 min for administering the rescue medication is not acceptable and should be reduced to 30 min.

2. Standard of care should be mentioned in the amended version of the protocol to be given to all patients in three sub-groups.

Also Read: NPPA exempts Torrent Pharma Tapentadol Nasal Spray from price cap for 5 years
tapentadol nasal spray cdsco sec committee phase 3 trials torrent pharma news Torrent Pharma 
Medical Dialogues Team
Medical Dialogues Team

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable  connection

    Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable connection

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Review: Efficacy of Antiviral Agents Against  Omicron Subvariant BA.2

    Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    View All

    Journal Club Today

    Unexpected effects of common painkillers that may be explained by a new study

    Unexpected effects of common painkillers that may be explained by a new study

    View All

    Health News Today

    Health Bulletin 25/May/2022

    Health Bulletin 25/May/2022

    View All
    © 2019 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X